STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
City of Hope Medical Center
City of Hope Medical Center
Hadassah Medical Organization
National Cancer Institute (NCI)
Lady Davis Institute
University of Kansas Medical Center
City of Hope Medical Center
GT Medical Technologies, Inc.
Orion Biotechnology Polska Sp. z o.o.
Merck Sharp & Dohme LLC
Turning Point Therapeutics, Inc.
Astellas Pharma Inc
Mayo Clinic
Methodist Health System
Nykode Therapeutics ASA
University of Arkansas
AdventHealth
University of Chicago
The University of Tennessee, Knoxville
Queen Mary University of London
J Ints Bio
Capital Medical University
QuantumLeap Healthcare Collaborative
Codagenix, Inc
City of Hope Medical Center
Turning Point Therapeutics, Inc.
Massachusetts General Hospital
Providence Health & Services
Targovax ASA
UMC Utrecht
CytoDyn, Inc.
Centre hospitalier de l'Université de Montréal (CHUM)
Federation Francophone de Cancerologie Digestive
Health Clinics Limited
Hoosier Cancer Research Network
Shanghai Henlius Biotech
Actuate Therapeutics Inc.
Ohio State University Comprehensive Cancer Center
The Cooper Health System
University of Colorado, Denver
NextCure, Inc.
Boston Scientific Corporation
University of California, San Francisco
University of California, San Francisco
NKGen Biotech, Inc.
Sun Yat-sen University
University of Miami
Eli Lilly and Company
Grupo Español Multidisciplinar de Melanoma
National Cancer Institute (NCI)
Institut de Cancérologie de la Loire